Sildenafil spray highly effective for men with ED with diabetes

Sixty patients were divided into two groups of 30 people. Group 1 patients had prediabetes, while group 2 had type 2 DM. All men had ED, and the severity was measured using the IIEF-5 (International Index of Erectile Function). To assess blood flow, Doppler ultrasound was done before and after treatment. Prediabetes patients used Sildenafil in the form of an oral spray (Gent) 25 mg (2 doses) once daily for one month, while those with type 2 DM received 50 mg (4 injections) every other day for one month. Most patients took metformin and followed diet therapy.

The main objective of this study was to analyze the outcomes of utilizing Sildenafil in the form of an oral spray (Gent) for the treatment of erectile dysfunction (ED) in males with type 2 diabetes mellitus (DM) and prediabetes.

Key findings of the study are:

• Sildenafil oral spray decreased body weight and waist circumference, a decrease in insulin and Hemoglobin A1C levels without changing hypoglycemic therapy in type 2 DM patients.
• In prediabetes patients, there was a decrease in fasting insulin levels.
• During treatment, half of the persons with impaired glucose metabolism had an increase in the testosterone level.
• There was reduced ED severity in both groups.
• In men with prediabetes, there was an increase in the average IIEF-5 score from 15.98 to 21.57 points. In Type 2 DM patients, it improved from 12.18 to 18.44 points.
• There was a significant increase in the maximum systolic blood flow velocity and arterial resistivity index after treatment with Sildenafil oral spray in patients with prediabetes and type 2 diabetes.

They said, "In our study, we found that Sildenafil oral spray can effectively treat ED in men with type 2 DM and prediabetes.

Reference:

Korenkov, D G., et al. "[Efficacy of Sildenafil Oral Spray for the Treatment of Erectile Dysfunction in Patients With Type 2 Diabetes Mellitus and Prediabetes]." Urologiia (Moscow, Russia: 1999), 2023, pp. 46-52.